Bank of America Securities Maintains Buy Rating on Insulet (PODD) Stock

Insulet Corporation (NASDAQ:PODD) is one of the Stocks with Potential to Explode in 2026. On June 10, Bank of America Securities analyst Travis Steed maintained a “Buy” rating on the company’s stock, setting a price objective of $208.00. The rating is backed by factors that mainly include the view that the company’s current share price already reflects the slower U.S. Omnipod growth profile.

The analyst’s modeling demonstrates that the expectations for mid‑teens to high‑teens growth in 2027–2028 remain achievable. This is even after assuming some erosion in Insulet Corporation (NASDAQ:PODD)’s share of new pump patients. Also, the analyst noted a wide range of upside if Omnipod maintains the new‑start share and there is faster-than-expansion in the insulin pump market, which can improve growth into the low‑ to mid‑20% range.

The analyst also sees Insulet Corporation (NASDAQ:PODD) growing EPS at a more than 25% compounded rate.

Insulet Corporation (NASDAQ:PODD) is engaged in developing, manufacturing, and selling insulin delivery systems for people with insulin-dependent diabetes.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.